# US 8,785,190 B2 · Methods and compositions for modulating peripheral immune function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,190 B2
- Document ID: US8785190B2
- Status: Granted
- Kind: B2
- Application number: 13/441,311
- Filed: 2012-04-06
- Published: 2013-04-18
- Granted: 2014-07-22
- Earliest claimed: 2011-04-06
- Assignees: SanBio, Inc.
- Applicants: Mo Dao; Casey C. Case
- Inventors: Mo Dao; Casey C. Case
- Web page: https://patentgrep.com/patent/US8785190B2

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 15/85: for animal cells
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2502/1358: Bone marrow mesenchymal stem cells (BM-MSC)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are cell preparations useful for modulating various peripheral immune functions, methods for making said cell preparations, and methods for their use.

## Claims

### Claim 1

A method for modulating production of one or more cytokines by a T-lymphocyte (T-cell) or a monocyte; the method comprising:
contacting the T-cell or monocyte with an effective amount of SB623 cells;
wherein said contacting results in stimulation of the production of one or more anti-inflammatory cytokines and/or inhibition of production of one or more pro-inflammatory cytokines by the T-cell or the monocyte;
further wherein said SB623 cells are obtained by
(a) providing a culture of marrow adherent stromal cells;
(b) contacting the cell culture of step (a) with a polynucleotide comprising sequences encoding the Notch intracellular domain (NICD) wherein said polynucleotide does not encode a full-length Notch protein;
(c) selecting cells that comprise the polynucleotide of step (b); and
(d) further culturing the selected cells of step (c) in the absence of selection for the polynucleotide, such that said marrow adherent stromal cells are induced to form SB623 cells by expression of the NICD.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pro-inflammatory cytokine is interferon gamma (IFN-γ).

### Claim 3 (depends on 1)

The method of claim 1, wherein the pro-inflammatory cytokine is tumor necrosis factor alpha (TNF-α).

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-inflammatory cytokine is interleukin-10 (IL-10).

### Claim 5 (depends on 1)

The method of claim 1, wherein the T cell is a helper T-cell.

### Claim 6 (depends on 5)

The method of claim 5, wherein the helper T-cell is a TH1 cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the T-cell is a regulatory T-cell.

### Claim 8 (depends on 7)

The method of claim 7, wherein the regulatory T-cell is a TR1 cell.

### Claim 9 (depends on 1)

The method of claim 1, wherein said modulation of cytokine production results in conversion of a T-cell population from one that is pro-inflammatory to one that is anti-inflammatory.